Organizational changes lead to a reduction in opioid consumption among chronic pain patients: A systematic review.

OBJECTIVE: To investigate the literature in terms of describing new ways to organize pain treatment for patients with chronic nonmalignant pain and the effect on opioid consumption. DESIGN: A systematic literature search was conducted in PubMed, CINAHL, REHABDATA, PsycINFO, and EMBASE using the methodology recommended by Cochrane. The data extraction was performed by Population, Intervention, Comparison, Outcome, and Time frame. The quality of the studies was rated by the Study Quality Assessment Tool or the revised Standards for Quality Improvement Reporting Excellence when suitable. SETTING: Primary care clinics. PATIENTS/PARTICIPANTS: Patients with chronic nonmalignant pain in high-dose opioid treatment connected to a primary care clinic or the employed healthcare professionals. MAIN OUTCOME MEASURES: The primary aim of this Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review was to investigate if an organizational change in the follow-up procedures has an effect on high-dose opioid consumption in patients with long-term nonmalignant pain. RESULTS: Out of 2,146 articles, 11 studies met the inclusion criteria, mainly of an observational character. The majority of the studies were rated as good quality studies. As for the risk of bias, five studies were rated unclear, one study rated as high risk, and four studies as low risk of bias. One study could not be rated. All studies demonstrated a reduction in opioid consumption. Two studies investigated patients' pain and quality of life, but no reduction was found between groups. CONCLUSION: The findings indicate that it is possible to detect a reduction in opioid consumption when a new follow-up procedure has been implemented.

Guided self-determination in treatment of chronic pain - a randomized, controlled trial.

OBJECTIVES: To test whether Guided Self-Determination (GSD) used in chronic pain management could improve the health-related quality of life, patient activation and sense of coherence (SoC) as a measurement of life skills in patients with chronic pain. The method has been shown to be effective in other chronic conditions, but has not been tested in chronic pain. METHODS: A three-site randomised, controlled trial at three major multidisciplinary pain centres in Denmark. 200 patients were included and randomised. In the intervention period, both groups had regular visits to the pain centre with both doctors and nurses. The intervention group additionally received the GSD intervention with weekly sessions for eight weeks. Data were collected from February 2013 to July 2016 and consisted of three questionnaires answered before and after the 8-week intervention period, and after six months. The primary outcome was self-reported health related quality of life. Secondary outcomes included self-reported activation and SoC. RESULTS: We found no clinically relevant difference between the groups for health-related quality of life, patient activation or SoC at either baseline, at three months or at six months. We also analysed data for trends over time using mixed model analysis, and this did not show any significant differences between groups. CONCLUSIONS: GSD did not improve health-related quality of life, patient activation or SoC when administered to patients with chronic pain treated in a multidisciplinary pain centre. New research is recommended using a combination of self-reported and objective measures and longer follow-up.

Cognitive Function During Opioid Tapering in Patients with Chronic Pain: A Prospective Cohort Study.

PURPOSE: Evidence for efficacy and safety lacks for long-term opioid therapy in patients with chronic non-cancer pain and adverse effects, including affection of cognitive function and quality of life, is of concern. We aimed to investigate cognitive function and health-related quality of life in patients with chronic non-cancer pain during opioid reduction. PATIENTS AND METHODS: At two multidisciplinary pain centers, all patients with planned opioid reduction were screened for eligibility. Cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Trail Making Test A and B. Health-related quality of life was assessed using Short Form-36 (SF36) and Hospital Anxiety and Depression Scale (HADS). RESULTS: We included 51 participants and 40 participants attended follow-up of median 254 (IQR 106-357) days. Baseline RBANS score was 82 (IQR 65-93) with reference population norm value of 100 (SD±15). Daily opioid consumption was reduced from median 80 (IQR 45-161) oral morphine milligram equivalents to 19 (IQR 0-60) mg. RBANS score estimate increased by 6.2 (95% CI 3.1-9.3, p=0.0004) points after tapering. No differences were observed for Trail Making Test times, HADS or SF36 scores. CONCLUSION: Generally, cognitive function showed minor improvement after opioid tapering with stationary health-related quality of life, depression and anxiety scores. The clinical significance is unclear, as no minimal clinically important difference in RBANS score is available.

[Opioids for chronic non-malignant pain].

In recent years, the use of opioids in Denmark has been under scrutiny due to various government measures to reduce consumption, greater media focus and Denmark's relatively larger consumption of opioids compared with the Nordic neighbours. Consequently, opioid prescriptions in Denmark have declined since 2017. A more nuanced approach to opioid treatment for non-malignant chronic pain, which includes individualised treatment as well as enhanced interdisciplinary collaboration, is required as argued in this review.